Abstract:Introduction: Prostate Cancer (PCa) is the second most diagnosed malignancy and the fifth leading cause of cancer deaths in men worldwide. Andrographolide, a labdane diterpenoid that is the main bioactive component of the medicinal plant Andrographis paniculata, has shown a wide range of therapeutic potential against many factors including cancer. Previous studies in our laboratory showed that Andrographolide induces expression of DNA repair genes associated with double-strand break repair, cell growth suppression, cell cycle arrest, and apoptosis in PCa in vitro. Andrographolide also showed an altered ATP production ratio between mitochondrial-ATP and glycolysis-ATP production in PC3 and 22RV1 cell lines treated with Andrographolide. However, the mechanism of action of Andrographolide in prostate cancer is not completely known. The objective of this study is to determine the role of Andrographolide in mtDNA damage, mitochondrial ROS production, and mitochondrial membrane potential in prostate cancer cell lines. Methods: Prostate cancer cell lines (PC3 and 22Rv1) were treated with Andrographolide (25μM) for 24 and 48 hours. DNA isolated from treated and control cells was used to detect mtDNA damage using a PCR-based method. To evaluate ROS production, cells were incubated with MitoSOX and fluorescence detected using fluorescence microscopy. Membrane potential status was also determined with fluorescence microscopy, using the dye JC-1. Results: Detection of mtDNA damage in PC3 cells treated with Andrographolide for 48 hours and in 22Rv1 cells treated with Andrographolide for 24 and 48 hours, show decreased mtDNA lesions in treated cells. Evaluation of mitochondrial membrane potential shows membrane depolarization in 22Rv1 cells treated with Andrographolide. In addition, mitochondrial ROS production shows a 1.4-fold increase in 22Rv1 cells treated with Andrographolide for 24 hours. Conclusion: This study shows that Andrographolide disrupts mitochondrial function in PC3 and 22Rv1 PCa cells, which in turn may trigger a metabolic phenotype leading to cell death PCa. This research could provide new insights into the role of Andrographolide in PCa altering bioenergetics and mitochondrial function, making Andrographolide a promising therapeutic candidate as a metabolic modulator and a chemo preventive agent in prostate cancer. Citation Format: Yarelis M. Roque-Reyes, Jesus Sosa-Rivera, María M. Sánchez-Vázquez, Sylvette Ayala-Peña, Carlos A. Torres-Ramos, Magaly Martínez-Ferrer. Andrographolide treatment results in decreased mtDNA damage and loss of the mitochondrial membrane potential while increasing ROS production in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 2343.

Abstract 2343: Andrographolide treatment results in decreased mtDNA damage and loss of the mitochondrial membrane potential while increasing ROS production in prostate cancer

Abstract C072: Andrographolide exhibits anti-cancer activity via restoring DNMT3B-suppressed ZNF382 expression in pancreatic cancer

Andrographolide Enhances 5-Fluorouracil-induced Apoptosis Via Caspase-8-dependent Mitochondrial Pathway Involving P53 Participation in Hepatocellular Carcinoma (SMMC-7721) Cells.

Cytotoxic Effect of Andrographis paniculata Associated with 2-Aminoethyl Dihydrogen Phosphate in Triple-Negative Breast Cells

Andrographolide inhibits non-small cell lung cancer cell proliferation through the activation of the mitochondrial apoptosis pathway and by reprogramming host glucose metabolism

Andrographolide suppresses the malignancy of pancreatic cancer via alleviating DNMT3B-dependent repression of tumor suppressor gene ZNF382

Andrographolide, a diterpene lactone from Andrographis paniculata and its therapeutic promises in cancer

Andrographolide Inhibits Breast Cancer Through Suppressing COX-2 Expression and Angiogenesis Via Inactivation of P300 Signaling and VEGF Pathway.

Andrographolide Exhibits Anticancer Potential Against Human Colon Cancer Cells by Inducing Cell Cycle Arrest and Programmed Cell Death via Augmentation of Intracellular Reactive Oxygen Species Level

Andrographolide Inhibits Proliferation and Promotes Apoptosis in Bladder Cancer Cells by Interfering with NF- Κ B and PI3K/AKT Signaling in Vitro and in Vivo.

Andrographolide suppresses aerobic glycolysis and induces apoptotic cell death by inhibiting pyruvate dehydrogenase kinase 1 expression

Andrographolide sensitizes prostate cancer cells to TRAIL-induced apoptosis.

Andrographolide Induces Autophagic Cell Death in Human Liver Cancer Cells Through Cyclophilin D-mediated Mitochondrial Permeability Transition Pore.

Andrographolide demonstrates anti-proliferative activity in oral cancer by promoting apoptosis, the programmed cell death process

Andrographolide induces protective autophagy and targeting DJ-1 triggers reactive oxygen species-induced cell death in pancreatic cancer

Andrographolide sensitizes cisplatin-induced apoptosis via suppression of autophagosome-lysosome fusion in human cancer cells.

Andrographolide Induces Cell Cycle Arrest at G2/M Phase and Cell Death in HepG2 Cells Via Alteration of Reactive Oxygen Species.

Andrographolide reverts multidrug resistance in KBChR 8‐5 cells through AKT signaling pathway

Effects of Andrographolide in Proliferation, Migration and Apoptosis of Renal Cell Carcinoma 786-0 Cells

Andrographolide Induces Autophagic Cell Death and Inhibits Invasion and Metastasis of Human Osteosarcoma Cells in an Autophagy-Dependent Manner.

Andrographolide enhanced radiosensitivity by downregulating glycolysis via the inhibition of the PI3K-Akt-mTOR signaling pathway in HCT116 colorectal cancer cells